Mingtao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mingtao Liu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Baoqing Sun
State Key Laboratory of Respiratory Disease The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
7 shared publications Baoqing Sun
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
5 shared publicationsMingshan Xue
Guangzhou Laboratory, Guangzhou, 510005, People’s Republic of China
4 shared publicationsZhangkai J. Cheng
Department of Clinical Laboratory, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
4 shared publications- Zhangkai Jason Cheng
Department of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
4 shared publications Haiyang Li
Department of Clinical Laboratory of the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, 510120, People’s Republic of China
3 shared publications
Latest Publications
- Open Access
- 4 July 2026
- Published by Elsevier in World Allergy Organization Journal
- Vol. 19 (8)
Machine learning-based MPO and Lp-PLA2 profiling reveals asthma-predominant inflammatory signature in asthma-COPD overlap
- 4 July 2026
- Published by Elsevier in World Allergy Organization Journal
- Vol. 19 (8)
Open AccessMachine learning-based MPO and Lp-PLA2 profiling reveals asthma-predominant inflammatory signature in asthma-COPD overlap
- 18 January 2025
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 26 (2) , 158-171
Thirteen serum biochemical indexes and five whole blood coagulation indices in a point-of-care testing analyzer: ideal protocol for evaluating pulmonary and critical care medicine
The accurate and timely detection of biochemical coagulation indicators is pivotal in pulmonary and critical care medicine. Despite their reliability, trad
- 18 January 2025
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 26 (2) , 158-171
Thirteen serum biochemical indexes and five whole blood coagulation indices in a point-of-care testing analyzer: ideal protocol for evaluating pulmonary and critical care medicine
The accurate and timely detection of biochemical coagulation indicators is pivotal in pulmonary and critical care medicine. Despite their reliability, trad
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA5178
A pilot HRCT follow-up study to test the feasibility of predictive efficacy of serum periostin in idiopathic pulmonary fibrosis
Background: While serum periostin and Krebs von den Lungen-6 (KL-6) have been acknowledged as independent markers in idiopathic pulmonary fibrosis (IPF) diagnosis, the clinical combinatory potential of these biomarkers combined with high-resolution computed tomography (HRCT) has yet to be fully explored. Methods: This retrospective study involved 780 participants, comprising 510 UIP-IPF patients and 270 healthy controls. All subjects underwent clinical and laboratory examinations, particularly the detection of periostin and KL-6 using ELISA with innovative HRCT fibrosis score evaluations at admission and discharge during hospitalization in UIP-IPF patients. Results: In our cohort of patients with IPF, the mean length of hospital stay was 195.27±11.18 days, and patients with reduced serum periostin levels had significantly improved survival. Intriguingly, anti-fibrotic treatment highly increased serum periostin levels, which also augmented in HRCT fibrosis score. Additionally, noteworthy pre- and after-treatment variations were also detected in immunological indicators such as CRP, IL-2, IL-4, IL-6, IL-10, and D-Dimer. Lastly, ROC analysis revealed the superior predictive ability of periostin, both individually and when amalgamated with HRCT fibrotic score, as opposed to KL-6. Conclusions: Our findings underscore the preeminence of serum periostin over KL-6 in UIP-IPF diagnosis, particularly when conjoined with HRCT fibrosis score.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA5178
A pilot HRCT follow-up study to test the feasibility of predictive efficacy of serum periostin in idiopathic pulmonary fibrosis
Background: While serum periostin and Krebs von den Lungen-6 (KL-6) have been acknowledged as independent markers in idiopathic pulmonary fibrosis (IPF) diagnosis, the clinical combinatory potential of these biomarkers combined with high-resolution computed tomography (HRCT) has yet to be fully explored. Methods: This retrospective study involved 780 participants, comprising 510 UIP-IPF patients and 270 healthy controls. All subjects underwent clinical and laboratory examinations, particularly the detection of periostin and KL-6 using ELISA with innovative HRCT fibrosis score evaluations at admission and discharge during hospitalization in UIP-IPF patients. Results: In our cohort of patients with IPF, the mean length of hospital stay was 195.27±11.18 days, and patients with reduced serum periostin levels had significantly improved survival. Intriguingly, anti-fibrotic treatment highly increased serum periostin levels, which also augmented in HRCT fibrosis score. Additionally, noteworthy pre- and after-treatment variations were also detected in immunological indicators such as CRP, IL-2, IL-4, IL-6, IL-10, and D-Dimer. Lastly, ROC analysis revealed the superior predictive ability of periostin, both individually and when amalgamated with HRCT fibrotic score, as opposed to KL-6. Conclusions: Our findings underscore the preeminence of serum periostin over KL-6 in UIP-IPF diagnosis, particularly when conjoined with HRCT fibrosis score.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA4836
Utilizing Deep Machine Learning to Disclose Hematological Indices and Biomarkers in Asthma-COPD Overlap
Background: Asthma-COPD overlap (ACO) combines both asthma and COPD features, and clues suggest that they undergo worse events than those either one alone. Methods: Using a dataset of hematological parameters collected retrospectively by deep machine learning to analyze from infants to nineties aged patients with ACO (n = 907), asthma (n = 31929), COPD (n = 15934), and healthy cases (n = 5181) in Southern China. This study focused on the potential differences in disease severity among asthma-COPD overlap, asthma, and COPD, as well as their effects on blood biochemical indicators, lung function indications, airway inflammation indicators, and lung microbial community. Bayesian and random forest prediction models were used to achieve visual monitoring of these diseases. Results: Through training and analysis with the deep learning model, we successfully identified biomarkers closely associated with the disease conditions of asthmatic and COPD patients from a vast amount of hematological data, such as FeNO and eosinophil count. These markers are involved in various biological processes, including inflammatory responses, immune regulation, and oxidative stress. Importantly, we discovered that these markers exhibit significant changes in the early stages of the diseases, suggesting their potential role in early diagnosis. Conclusion: Our study demonstrates for the first time that through the use of deep learning, we can mine hematological biomarkers related to asthma and COPD, such as FeNO and eosinophil count, from large-scale blood data. These markers offer new insights for clinical diagnosis and treatment.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA4836
Utilizing Deep Machine Learning to Disclose Hematological Indices and Biomarkers in Asthma-COPD Overlap
Background: Asthma-COPD overlap (ACO) combines both asthma and COPD features, and clues suggest that they undergo worse events than those either one alone. Methods: Using a dataset of hematological parameters collected retrospectively by deep machine learning to analyze from infants to nineties aged patients with ACO (n = 907), asthma (n = 31929), COPD (n = 15934), and healthy cases (n = 5181) in Southern China. This study focused on the potential differences in disease severity among asthma-COPD overlap, asthma, and COPD, as well as their effects on blood biochemical indicators, lung function indications, airway inflammation indicators, and lung microbial community. Bayesian and random forest prediction models were used to achieve visual monitoring of these diseases. Results: Through training and analysis with the deep learning model, we successfully identified biomarkers closely associated with the disease conditions of asthmatic and COPD patients from a vast amount of hematological data, such as FeNO and eosinophil count. These markers are involved in various biological processes, including inflammatory responses, immune regulation, and oxidative stress. Importantly, we discovered that these markers exhibit significant changes in the early stages of the diseases, suggesting their potential role in early diagnosis. Conclusion: Our study demonstrates for the first time that through the use of deep learning, we can mine hematological biomarkers related to asthma and COPD, such as FeNO and eosinophil count, from large-scale blood data. These markers offer new insights for clinical diagnosis and treatment.
- Open Access
- 1 September 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 6729-6742
A Pilot HRCT Follow-Up Study to Test the Feasibility of Predictive Efficacy of Serum Periostin in Idiopathic Pulmonary Fibrosis
Background: While serum periostin and Krebs von den Lungen-6 (KL-6) have been acknowledged as independent markers in idiopathic pulmonary fibrosis (IPF) diagnosis, the clinical combinatory potential of these biomarkers combined with high-resolution computed tomography (HRCT) has yet to be fully explored. Methods: This retrospective study involved 78 participants, comprising 51 UIP-IPF patients and 27 healthy controls. All subjects underwent clinical and laboratory examinations, particularly the detection of periostin and KL-6 using ELISA with innovative HRCT fibrosis score evaluations at admission and discharge during hospitalization in UIP-IPF patients. Results: In our cohort of patients with IPF, predominantly male, over an average follow-up period of 195.27 days. Serum levels of periostin and KL-6 were significantly elevated in IPF patients compared to healthy controls (*p < 0.05). Post-treatment, KL-6 levels decreased significantly, while periostin levels increased. Notably, periostin exhibited superior prognostic accuracy over KL-6, with a higher AUC of 0.875 than 0.639 in ROC analysis. An increase in periostin levels correlated with disease progression, as evidenced by worsened HRCT fibrotic scores and decreased survival probability. These findings underscore periostin’s potential as a reliable biomarker for assessing IPF severity and therapeutic response. Conclusion: Our findings underscore the preeminence of serum periostin over KL-6 in UIP-IPF diagnosis, particularly when conjoined with HRCT fibrosis score.
- 1 September 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 6729-6742
Open AccessA Pilot HRCT Follow-Up Study to Test the Feasibility of Predictive Efficacy of Serum Periostin in Idiopathic Pulmonary Fibrosis
Background: While serum periostin and Krebs von den Lungen-6 (KL-6) have been acknowledged as independent markers in idiopathic pulmonary fibrosis (IPF) diagnosis, the clinical combinatory potential of these biomarkers combined with high-resolution computed tomography (HRCT) has yet to be fully explored. Methods: This retrospective study involved 78 participants, comprising 51 UIP-IPF patients and 27 healthy controls. All subjects underwent clinical and laboratory examinations, particularly the detection of periostin and KL-6 using ELISA with innovative HRCT fibrosis score evaluations at admission and discharge during hospitalization in UIP-IPF patients. Results: In our cohort of patients with IPF, predominantly male, over an average follow-up period of 195.27 days. Serum levels of periostin and KL-6 were significantly elevated in IPF patients compared to healthy controls (*p < 0.05). Post-treatment, KL-6 levels decreased significantly, while periostin levels increased. Notably, periostin exhibited superior prognostic accuracy over KL-6, with a higher AUC of 0.875 than 0.639 in ROC analysis. An increase in periostin levels correlated with disease progression, as evidenced by worsened HRCT fibrotic scores and decreased survival probability. These findings underscore periostin’s potential as a reliable biomarker for assessing IPF severity and therapeutic response. Conclusion: Our findings underscore the preeminence of serum periostin over KL-6 in UIP-IPF diagnosis, particularly when conjoined with HRCT fibrosis score.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1158
Enhancing the Detection of Interstitial Pneumonia with Autoimmune Features and Idiopathic Pulmonary Fibrosis through the Harmony of Matrix Metalloproteinases and Clinical Diagnosis
Background: Higher detection of interstitial pneumonia with autoimmune features (IPAF), and idiopathic pulmonary fibrosis (IPF) has significant diagnostic and therapeutic implications. Some matrix metalloproteinases (MMPs) have become reliable diagnostic biomarkers in IPAF and IPF in previous studies, yet relevant reliability remains to be recognized. Material and Methods: 36 ILDs patients, including 31 IPAF patients (Mean ± SD, 50.20 ± 5.10 years; 16 (51.6%) females) and 5 IPF patients (Mean ± SD, 61.20 ± 6.73 years; 1 (20.0%) females) were retrospectively enrolled. Serial serum samples were collected from patients with IPAF and IPF between January 2019 and December 2020. Notably, Serum MMPs levels were measured by U-PLEX Biomarker Group 1(Human) Multiplex Assays (MSD, USA). Results: A combination of MMPs and combinatorial biomarkers was strongly associated with clinical subjects in this study (AUC, 0.597 for Stability vs. Improvement and 0.756 for Stability vs. Exacerbation). Importantly, the AUC of MMP-12 reaches 0.730 (P<0.05, Stability AUC vs. Improvement AUC) while MMP-13 reaches 0.741 (P<0.05, Stability AUC vs. Exacerbation AUC) showed better performance than other MMPs in two comparisons. Conclusions: Clinical risk factors and MMPs are strongly associated with either stratification of the disease of progression of IPAF or in two IPAF and IPF independent cohorts. To our knowledge, this is the first to illustrate that MMP-12 and MMP-13 may be expected to become typical promising biomarkers in Improvement - IPAF and Exacerbation - IPAF, respectively.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1158
Enhancing the Detection of Interstitial Pneumonia with Autoimmune Features and Idiopathic Pulmonary Fibrosis through the Harmony of Matrix Metalloproteinases and Clinical Diagnosis
Background: Higher detection of interstitial pneumonia with autoimmune features (IPAF), and idiopathic pulmonary fibrosis (IPF) has significant diagnostic and therapeutic implications. Some matrix metalloproteinases (MMPs) have become reliable diagnostic biomarkers in IPAF and IPF in previous studies, yet relevant reliability remains to be recognized. Material and Methods: 36 ILDs patients, including 31 IPAF patients (Mean ± SD, 50.20 ± 5.10 years; 16 (51.6%) females) and 5 IPF patients (Mean ± SD, 61.20 ± 6.73 years; 1 (20.0%) females) were retrospectively enrolled. Serial serum samples were collected from patients with IPAF and IPF between January 2019 and December 2020. Notably, Serum MMPs levels were measured by U-PLEX Biomarker Group 1(Human) Multiplex Assays (MSD, USA). Results: A combination of MMPs and combinatorial biomarkers was strongly associated with clinical subjects in this study (AUC, 0.597 for Stability vs. Improvement and 0.756 for Stability vs. Exacerbation). Importantly, the AUC of MMP-12 reaches 0.730 (P<0.05, Stability AUC vs. Improvement AUC) while MMP-13 reaches 0.741 (P<0.05, Stability AUC vs. Exacerbation AUC) showed better performance than other MMPs in two comparisons. Conclusions: Clinical risk factors and MMPs are strongly associated with either stratification of the disease of progression of IPAF or in two IPAF and IPF independent cohorts. To our knowledge, this is the first to illustrate that MMP-12 and MMP-13 may be expected to become typical promising biomarkers in Improvement - IPAF and Exacerbation - IPAF, respectively.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1141
Exploring the Potential of Serum Periostin as a Predictive biomarker for Early-Onset Idiopathic Pulmonary Fibrosis: A Follow-Up Study
Background: The diagnostic value of periostin and Krebs von den Lungen-6 (KL-6) in idiopathic pulmonary fibrosis (IPF) has been reported, but the superiority of serum periostin or KL-6 as a biomarker in early-onset IPF is yet to be determined. Methods: A total of 51 IPF patients with anti-fibrotic therapy who underwent twice high-resolution computed tomography (HRCT) fibrosis scoring evaluation and 27 healthy controls were retrospectively enrolled from the First Affiliated Hospital of Guangzhou Medical University between January 2020 and May 2022. Serum levels of periostin and KL-6 by enzyme-linked immunosorbent assay (ELISA) and clinical diagnosis test were evaluated in both cohorts. Results: The levels of serum KL-6 levels in patients with initial diagnosis and with anti-fibrotic therapy decreased from 1680.71 ± 1842.60U/mL to 1263.25 ± 1488.19 U/mL (P 0.1118), while KL-6 showed a better when total fibrosis score > 100, namely in the later stage of IPF (r: 0.2197 > 0.1050). Conclusions: Our findings indicate that serum periostin expression was more remarkable than KL-6 in the early-onset IPF diagnosis (Total fibrosis score < 100), and innovative HRCT fibrosis score stratification was a significant extention in IPF patients.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1141
Exploring the Potential of Serum Periostin as a Predictive biomarker for Early-Onset Idiopathic Pulmonary Fibrosis: A Follow-Up Study
Background: The diagnostic value of periostin and Krebs von den Lungen-6 (KL-6) in idiopathic pulmonary fibrosis (IPF) has been reported, but the superiority of serum periostin or KL-6 as a biomarker in early-onset IPF is yet to be determined. Methods: A total of 51 IPF patients with anti-fibrotic therapy who underwent twice high-resolution computed tomography (HRCT) fibrosis scoring evaluation and 27 healthy controls were retrospectively enrolled from the First Affiliated Hospital of Guangzhou Medical University between January 2020 and May 2022. Serum levels of periostin and KL-6 by enzyme-linked immunosorbent assay (ELISA) and clinical diagnosis test were evaluated in both cohorts. Results: The levels of serum KL-6 levels in patients with initial diagnosis and with anti-fibrotic therapy decreased from 1680.71 ± 1842.60U/mL to 1263.25 ± 1488.19 U/mL (P 0.1118), while KL-6 showed a better when total fibrosis score > 100, namely in the later stage of IPF (r: 0.2197 > 0.1050). Conclusions: Our findings indicate that serum periostin expression was more remarkable than KL-6 in the early-onset IPF diagnosis (Total fibrosis score < 100), and innovative HRCT fibrosis score stratification was a significant extention in IPF patients.
- 15 June 2023
- Published by Wiley in Reviews in Medical Virology
- Vol. 33 (5) , e2464
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
The COVID‐19 pandemic represents an unparalleled global public health crisis. Despite concerted research endeavours, the repertoire of effective treatment options remains limited. However, neutralising‐antibody‐based therapies hold promise across an array of practices, encompassing the prophylaxis and management of acute infectious diseases. Presently, numerous investigations into COVID‐19‐neutralising antibodies are underway around the world, with some studies reaching clinical application stages. The advent of COVID‐19‐neutralising antibodies signifies the dawn of an innovative and promising strategy for treatment against SARS‐CoV‐2 variants. Comprehensively, our objective is to amalgamate contemporary understanding concerning antibodies targeting various regions, including receptor‐binding domain (RBD), non‐RBD, host cell targets, and cross‐neutralising antibodies. Furthermore, we critically examine the prevailing scientific literature supporting neutralising antibody‐based interventions, and also delve into the functional evaluation of antibodies, with a particular focus on in vitro (vivo) assays. Lastly, we identify and consider several pertinent challenges inherent to the realm of COVID‐19‐neutralising antibody‐based treatments, offering insights into potential future directions for research and development.
- 15 June 2023
- Published by Wiley in Reviews in Medical Virology
- Vol. 33 (5) , e2464
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
The COVID‐19 pandemic represents an unparalleled global public health crisis. Despite concerted research endeavours, the repertoire of effective treatment options remains limited. However, neutralising‐antibody‐based therapies hold promise across an array of practices, encompassing the prophylaxis and management of acute infectious diseases. Presently, numerous investigations into COVID‐19‐neutralising antibodies are underway around the world, with some studies reaching clinical application stages. The advent of COVID‐19‐neutralising antibodies signifies the dawn of an innovative and promising strategy for treatment against SARS‐CoV‐2 variants. Comprehensively, our objective is to amalgamate contemporary understanding concerning antibodies targeting various regions, including receptor‐binding domain (RBD), non‐RBD, host cell targets, and cross‐neutralising antibodies. Furthermore, we critically examine the prevailing scientific literature supporting neutralising antibody‐based interventions, and also delve into the functional evaluation of antibodies, with a particular focus on in vitro (vivo) assays. Lastly, we identify and consider several pertinent challenges inherent to the realm of COVID‐19‐neutralising antibody‐based treatments, offering insights into potential future directions for research and development.
- Open Access
- 29 May 2023
- Published by Wiley in Precision Medical Sciences
- Vol. 12 (3) , 134-143
The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases
- 29 May 2023
- Published by Wiley in Precision Medical Sciences
- Vol. 12 (3) , 134-143
Open AccessThe application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases
- Open Access
- 8 November 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (22) , 14663
Prevalence and Disability-Adjusted Life Year Rates of Asthma in China: Findings from the GBD Study 2019 of the G20
Background: The credible materials about the burden of asthma in China when compared to other countries in the group of twenty (G20) remain unavailable. Objectives and design: Following the popular analysis strategy used in the Global Burden of Disease Study, the age-, sex-, country-specific prevalence, and disability-adjusted life years (DALYs) of asthma in China were analyzed. Meanwhile, the comparison in trends between China and other countries in the G20 was also evaluated. Results: In 2019, asthma was the 8th leading cause of the DALYs’ burden of 369 diseases in China. From 1990 to 2019, the age-standardized prevalence and DALY rates of asthma in China decreased by 14% and 51%, respectively; further, the decline rate of DALYs was much higher than the global average (−51%: −43%). It is worth noting that the overall population age-standardized DALYs rate of asthma in China was the lowest in the G20 during 2019 (102.81, 95% UI: (72.30,147.42)/100,000). Moreover, the age-standardized asthma prevalence rate peaks in both childhood (178.14, 95% UI: (90.50, 329.01)/100,000) and the elderly (541.80, 95% UI: (397.79, 679.92)/100,000). Moreover, throughout the study, subjects in the 5 to 9 years old interval were a constant focus of our attention. Conclusions: The disease burden of asthma has varied greatly by gender and age over the past 30 years. In contrast to the increasing burden in most other G20 countries, the age-standardized prevalence rate of asthma shows a significant decreasing trend in China, however, the age-standardized DALYs rate shows a fluctuating change, and has even shown a rebound trend in recent years.
- 8 November 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (22) , 14663
Open AccessPrevalence and Disability-Adjusted Life Year Rates of Asthma in China: Findings from the GBD Study 2019 of the G20
Background: The credible materials about the burden of asthma in China when compared to other countries in the group of twenty (G20) remain unavailable. Objectives and design: Following the popular analysis strategy used in the Global Burden of Disease Study, the age-, sex-, country-specific prevalence, and disability-adjusted life years (DALYs) of asthma in China were analyzed. Meanwhile, the comparison in trends between China and other countries in the G20 was also evaluated. Results: In 2019, asthma was the 8th leading cause of the DALYs’ burden of 369 diseases in China. From 1990 to 2019, the age-standardized prevalence and DALY rates of asthma in China decreased by 14% and 51%, respectively; further, the decline rate of DALYs was much higher than the global average (−51%: −43%). It is worth noting that the overall population age-standardized DALYs rate of asthma in China was the lowest in the G20 during 2019 (102.81, 95% UI: (72.30,147.42)/100,000). Moreover, the age-standardized asthma prevalence rate peaks in both childhood (178.14, 95% UI: (90.50, 329.01)/100,000) and the elderly (541.80, 95% UI: (397.79, 679.92)/100,000). Moreover, throughout the study, subjects in the 5 to 9 years old interval were a constant focus of our attention. Conclusions: The disease burden of asthma has varied greatly by gender and age over the past 30 years. In contrast to the increasing burden in most other G20 countries, the age-standardized prevalence rate of asthma shows a significant decreasing trend in China, however, the age-standardized DALYs rate shows a fluctuating change, and has even shown a rebound trend in recent years.